Explore Global Companies & Account Intelligence

We seek out entrepreneurial business opportunities in biotech and pharmaceuticals and strive to take them to market. We also share our expertise through consulting with companies like yours at all stages in order to help you meet your goals. We have over 20 years of consulting experience working in Academic, Biotech, and Pharmaceutical Industry settings. We have been involved in start-ups as well as Big Pharma. We have been trained by National Academy members and Nobel Laureates. We have both business and research expertise. Whatever your need, we can fill it.

Comprehensive enterprise dossier available in global intelligence registry.

Cytomine cooperative develop the Open Source Software Cytomine and manage its community

Cyton is a full-service consultancy providing specialist support in REGULATORY AFFAIRS and multi-disciplinary PRODUCT DEVELOPMENT for the ANIMAL HEALTH industry. We have offices in Bristol, UK and Mannheim, Germany. Cyton's expertise covers VETERINARY MEDICINES (pharmaceuticals and immunologicals / vaccines), FEED ADDITIVES and borderline products. Our extensive experience covers all major species (dogs, cats, cattle, sheep, pigs, chickens, salmon) and a huge range of minor species (including horses, turkeys, rabbits and foxes). Our team includes experts in chemistry, manufacturing and controls (CMC) for your quality projects, toxicologists for your safety projects and veterinarians for your clinical projects. In addition, with our separate, dedicated regulatory procedures team, you can be sure that all of your regulatory submissions will run smoothly.

Cyton is a full-service consultancy providing specialist support in REGULATORY AFFAIRS and multi-disciplinary PRODUCT DEVELOPMENT for the ANIMAL HEALTH industry. We have offices in Bristol, UK and Mannheim, Germany. Cyton's expertise covers VETERINARY MEDICINES (pharmaceuticals and immunologicals / vaccines), FEED ADDITIVES and borderline products. Our extensive experience covers all major species (dogs, cats, cattle, sheep, pigs, chickens, salmon) and a huge range of minor species (including horses, turkeys, rabbits and foxes). Our team includes experts in chemistry, manufacturing and controls (CMC) for your quality projects, toxicologists for your safety projects and veterinarians for your clinical projects. In addition, with our separate, dedicated regulatory procedures team, you can be sure that all of your regulatory submissions will run smoothly.

World's first Handy Motorbike Covering Device - BIKE BLAZER Invented & Patented by CYTON Mind with Vision pvt ltd. Launched on 14Nov'16 Co founded by Mech. Engineer *Keashav Rai (22, having 2 International PATENTS), with his Mother *Raenu Rai (good to have a female onboard :D) Startup's Aim is to keep on Inventing products that impact lives on Millions of people for good. Niche market, that's where the Real money is. Right now, we're chasing our Aim with Bike Blazer. 2530+ Bike Blazer users in INDIA & NEPAL, within 8 months, has it's presence in 4 Indian States & Nepal. In the Media: The HINDU, INDIA TV, Dainik Bhaskar, Punjab Kesari, Navodya Times

Cytonn Investments is an investments and real estate company, with offices in Nairobi - Kenya and DC Metro area. We are primarily focused on offering alternative investment solutions to global institutional investors, individual high net-worth investors, local institutional investors and diaspora investors interested in the East-African region. Our alternative investments solutions are based on four main products: real estate, structured solutions, private equity and advisory. Most of the investment opportunities in Sub Saharan Africa are not in the listed markets, hence our focus on alternative investments to find uncommon value and returns for our clients.

Cytonn Investments is an investments and real estate company, with offices in Nairobi - Kenya and DC Metro area. We are primarily focused on offering alternative investment solutions to global institutional investors, individual high net-worth investors, local institutional investors and diaspora investors interested in the East-African region. Our alternative investments solutions are based on four main products: real estate, structured solutions, private equity and advisory. Most of the investment opportunities in Sub Saharan Africa are not in the listed markets, hence our focus on alternative investments to find uncommon value and returns for our clients.

Cytonn Investments is an investments and real estate company, with offices in Nairobi - Kenya and DC Metro area. We are primarily focused on offering alternative investment solutions to global institutional investors, individual high net-worth investors, local institutional investors and diaspora investors interested in the East-African region. Our alternative investments solutions are based on four main products: real estate, structured solutions, private equity and advisory. Most of the investment opportunities in Sub Saharan Africa are not in the listed markets, hence our focus on alternative investments to find uncommon value and returns for our clients.

Bacteriophages are viruses that specifically target and destroy bacterial cells. Cytophage uses synthetic biology to generate any type of bacteriophage in the lab, replacing that ‘search-in-nature’ process and accelerating the development and application of bacteriophages to prevent or treat infections. This would serve as a complement to antibiotics and help tackle the global problem of antibiotic resistance. Our vision for Cytophage is that every hospital, every veterinarian and every agricultural facility will have a supply of Cytophage products to manage any incumbent or emergent bacterial infection or contamination.

Comprehensive enterprise dossier available in global intelligence registry.

Cytovac has the key to immunotherapy Cytovac is a growing Danish biotech company, focusing on development of a cancer treatment that uses the bodys own immune system. Promising results gained by the dedicated research team over a number of years, have brought about the development of the ALECSAT therapy. ALECSAT is a therapy based on injection of activated cells from the immune system. These cells will attack the cancer cells and activate the immune system in the patients. As Cytovac solely apply the patients own cells, this therapy is gentle and without the serious side effects normally associated with cancer treatment. Cytovac has been granted Orphan Drug Designation by the European (EMA) as well as the American (FDA) medicines agencies in support to the companys brain-cancer project. Cytovac has generated convincing data with the ALECSAT treatments in three clinical phase I trials targeted at treatment of prostate cancer, pancreatic cancer and brain cancer. So far more than 100 cancer patients have been treated, with more than 250 doses of ALECSAT. So Cytovac has a platform that may prove to be an efficacious treatment for several types of cancer. Cytovac has since 2015 concentrated all clinical efforts on brain cancer, and here the company is currently conducting clinical phase II trials. Cytovac is dedicated to treatment of cancer by using our key to immunotherapy.